Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRaß+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Transplantation & Cellular Therapy Consortium (PTCTC) PIDTC \"CSIDE\" Protocol (Conditioning SCID Infants Diagnosed Early) PTCTC NMD 1801
NCT Number:
NCT03619551
Phase:
II
Protocol Type:
Treatment
Age Group:
Children
Disease Sites:
Hodgkin's Lymphoma, Leukemia, other, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma
Study Objectives:
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants.
Study Documents
(MUSC NetID required for document access)